Brittany Lovely


FDA Schedules ODAC Meetings to Review Pending Drug Applications

August 06, 2022

The FDA has scheduled 3 sessions for the Oncologic Drugs Advisory Committee to review updates on the new drug application for poziotinib tablets and data for the continued approval of indications for melphalan flufenamide and duvelisib.